Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Views & Analysis 2021 market access prospects for Germany The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
